92 stories found
Eli Lilly is losing market share in India's GLP-1 market due to the influx of cheap semaglutide generics, while Novo Nordisk maintains its position through price cuts for Ozempic and Wegovy.
The patent for semaglutide, the active ingredient in Ozempic and Wegovy, expired in several countries, leading to a surge of cheap generic versions in Asia. This development has raised concerns about potential weight-loss abuse.
Novo Nordisk's new Wegovy pill has seen an explosive launch, drawing a new wave of patients into GLP-1 weight loss treatments. CNBC interviewed five U.S. patients who shared their varying initial experiences with the drug following its introduction.
The U.S. Food and Drug Administration has approved Eli Lilly's new oral GLP-1 weight loss pill, Foundayo, offering a convenient alternative to injections and expanding market options while intensifying competition with Novo Nordisk's Wegovy.
The British health system is set to expand its offering of the weight-loss drug Wegovy to more than one million overweight patients who are at risk of heart attacks.
Novo Nordisk has introduced multi-month subscription plans for its obesity drug, Wegovy, offering lower monthly pricing and expanding sales channels to include platforms like Hims and LifeMD to compete with rivals.
Scientists are scrutinizing weight-loss drugs like Wegovy, which have revolutionized medicine, to investigate a rare but potential risk of eye damage, as their growing popularity raises new safety questions.
New studies indicate that Wegovy, a widely used obesity medication, may be linked to a rare but severe complication known as 'eye stroke,' which can lead to sudden vision loss.
Novo Nordisk's higher dose version of its weight-loss drug Wegovy has received approval in the U.S., expanding treatment options for patients.
Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.
Novo Nordisk's weight-loss drug, Wegovy, has received approval from U.S. regulators for a higher dose. This development expands the treatment options available for weight management.
Novo Nordisk Hellas announces the price reduction of the product Wegovy® according to the following table, effective March 18, 2026.
Novo Nordisk is appealing the decision to deny a subsidy for its obesity drug Wegovy in Sweden. The company is challenging the ruling that impacts the accessibility of the medication.
Leki przeciwcukrzycowe, takie jak Ozempic i Wegovy, zyskały w ostatnim czasie ogromną popularność jako środki na odchudzanie.
A major holder of shares in Novo Nordisk, the maker of Wegovy, saw their asset value cut by a third following a crash related to the company's performance.
Patients taking Wegovy are five times more at risk of sudden vision loss compared to those taking Ozempic, a new large study has shown.
The weight-loss jab Wegovy may carry the highest risk of sudden sight loss compared to other semaglutide drugs such as Ozempic, according to new analysis.
Novo Nordisk and Hims & Hers are reportedly exploring a potential partnership to collaborate on the sale of obesity drugs.
Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries Weight-loss jabs such as Wegovy and Ozempic could be made for just $3 a month,…
Forskarar trur at slankemedisinen Wegovy kan hjelpe med både vekt, hukommelse og den mentale helsa.
Novo Nordisk has commenced a €432 million upgrade of its facility in Ireland to boost the production of oral Wegovy.
Novo Nordisk gør klar til at producere blandt andet Wegovy på pilleform på nye anlæg i Irland.
Five percent of Icelanders using Wegovy Iceland Monitor
Danish pharmaceutical giant Novo Nordisk announced a significant 50% price reduction in the United States for its leading obesity and diabetes medications, Wegovy and Ozempic.
Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50% WSJ
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.
Novo Nordisk to halve US list price of Wegovy from 2027 Reuters
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
A report indicates that five percent of the Icelandic population is currently using the weight-loss medication Wegovy.
In 2025, 16,692 Icelanders used weight-loss drugs like Wegovy and Saxenda, spending nearly 3.5 billion Icelandic krónur annually, averaging over 200,000 krónur per person.
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.
Novo Nordisk has launched the high-dose version of its GLP-1 injection, Wegovy, at a price point $50 lower than Eli Lilly's competing drug, Zepbound. This strategic pricing aims to position Wegovy competitively in the market.
Wegovy has introduced a new subscription service that could allow users to save up to $1,200 on the medication.
NHS England plans to provide weight-loss drugs to 1.2 million overweight individuals, with Britain's drug price regulator NICE recommending Wegovy, significantly expanding its access on the NHS and further extending its reach in the UK.
The British drug-cost watchdog has recommended the use of Novo Nordisk's drug Wegovy to help lower heart risks.
Novo Nordisk has reduced the prices of its popular drugs Ozempic and Wegovy in India, a move made in response to the growing threat of generic competition in the market.
Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.
The FDA has approved Wegovy HD, a higher-dose semaglutide, for weight loss in adults with obesity, offering a 'major jump' in potential weight reduction, with some users losing an average of 21 percent of their body weight.
Indian pharmaceutical companies are launching cheaper generic versions of Novo Nordisk's popular weight-loss and diabetes drugs, Ozempic and Wegovy, initiating a price war in the market.
Novo Nordisk’s Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval WSJ
US FDA approves higher dose of Novo's Wegovy under new fast-track review program Reuters
Drugs like Ozempic, Wegovy, or Mounjaro have changed the game. In some patients, they lead to weight loss, which was practically unattainable without surgery until recently.
This experimental pill helped people lose about 16% of their body weight after about a year of treatment
Antidiabetic drugs, such as Ozempic and Wegovy, have recently gained immense popularity as weight loss agents.
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
STUDIJA je otkrila da lijek za mršavljenje Wegovy nosi gotovo pet puta veći rizik od iznenadnog gubitka vida, tzv. 'očnog udara', u usporedbi s lijekom za dijabetes Ozempic.
‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author Patients taking Wegovy have nearly five times the risk of sudden sight loss…
Novo Nordisk is implementing price reductions for its popular drugs Ozempic and Wegovy, a strategic move that analysts suggest could ultimately benefit the company's stock performance.
Novo Nordisk has announced price reductions of up to 17.6% for its diabetes and obesity drugs, Ozempic and Wegovy, in Spain, with Wegovy's highest dose dropping to 223.64 euros.
Data from the National Association of Pharmacies indicates a significant increase in obesity medication sales in 2025, largely driven by the market entry of Mounjaro and Wegovy in Portugal.
Danish drugmaker Novo Nordisk is investing in a new facility in Ireland to expand its production capacity for the newly launched weight-loss pill Wegovy, aiming to compete with Eli Lilly.
Novo Nordisk is reportedly investing $507 million in a new plant for its Wegovy pill, as reported by the Irish Times.
Novo Nordisk experienced a challenging week, with its stock losing all gains previously attributed to the success of its drug, Wegovy.
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
Novo Nordisk announced significant reductions, up to 50%, in the U.S. list prices for its popular drugs Ozempic and Wegovy.
Novo Nordisk plans to reduce the prices of its popular weight-loss and diabetes drugs, Ozempic and Wegovy, starting in 2027, a move that could impact patient access and market dynamics.
The European Commission has approved a new 7.2 mg weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing an additional therapeutic option for those requiring greater weight loss.
Novo Nordisk experienced a significant decline, with its $475-billion gains from the Wegovy era being wiped out.
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) has decided against subsidizing the weight-loss medication Wegovy, a decision confirmed by manufacturer Novo Nordisk.
Right now, the Wegovy pill is surging in the USA. At the same time, Novo Nordisk is testing a new pill which, according to head of research Martin Holst Lange, has the potential to sweep all future pill competitors off the market.
A Korean doctor issues a public warning about fraudulent 'oral Wegovy' weight loss supplements, advising consumers that these products are 100% scams.
Research suggests that an individual's genetic predisposition can play a role in how effectively weight-loss medications such as Wegovy and Mounjaro work, with some people losing less weight even with medication.
Novo Nordisk has introduced a higher-dose version of its Wegovy weight-loss shot in the United States market, expanding its offerings for GLP-1 treatments.
Eli Lilly's stock has seen a significant rise following the approval of its GLP-1 pill, intensifying competition in the weight-loss drug market with Novo Nordisk's Wegovy. Analysts continue to favor Eli Lilly's Foundayo, adding a financial dimension to the ongoing market battle and prompting investment discussions, with new approvals potentially marking a turning point for Novo Nordisk.
Novo Nordisk's weight-loss drug, Wegovy, is set to become available to an additional 1.2 million patients across England.
Novo Nordisk has once again reduced the prices of its popular drugs Ozempic and Wegovy in India, a strategic move aimed at competing with cheaper generic alternatives in the market.
Generic versions of popular weight-loss medications like Ozempic and Wegovy are anticipated to become available in Canadian pharmacies this summer, offering more affordable alternatives to patients currently paying $300-$400 monthly for brand-name drugs. This development could significantly impact access and cost for weight management treatments.
People taking ‘Wegovy HD’ lost an average of 21 percent of their body weight after 72 weeks
The FDA has approved Wegovy HD, a higher-dose semaglutide, for weight loss in adults with obesity, promising greater weight reduction despite expert warnings about potential side effects.
The patents for popular drugs Ozempic and Wegovy are expiring in various countries, paving the way for the production of generic versions to begin as early as this weekend.
Novo Nordisk has received approval in the United States for a higher dose of its weight-loss medication, Wegovy, with plans to launch the new dosage in the US market in April.
Jót tehet a szívének a Wegovy, az Ozempic és a többi, GLP-1-alapú gyógyszer, de a hatás nem tart örökké, csak addig, amíg szedi őket.
V Indiji poteče patent za semaglutid – učinkovino v zdravilih Wegovy in Ozempic podjetja Novo Nordisk. Bo to spremenilo globalno sliko zdravljenja debelosti?
American restaurant chains are reconsidering both menus and portion sizes after the use of so-called GLP-1 drugs, such as Ozempic, Wegovy, and Zepbound, has increased significantly.
Researchers reveal that generic injectable semaglutide, the main ingredient in Ozempic and Wegovy, could cost between $28 and $140 (about 24 and 121 euros) per year.
Wegovy may carry the highest risk of “eye stroke” and sudden sight loss of weight-loss jabs, according to a new analysis.
The American authority notes alleged gaps in procedures for adverse reactions in the use of drugs for diabetes and obesity. The Danish giant launches a plan to correct course
New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.
Pounds melt away with weight loss injections. However, the treatment will likely have to be continued lifelong, otherwise the weight threatens to increase rapidly again. A small deficit can possibly be saved.
Novo Nordisk, the company behind the injectable weight-loss drug Wegovy, plans to invest €430 million in its Athlone plant to enhance the production of Wegovy in pill form.
Pharmaceutical company Novo Nordisk announced a €430 million expansion of its manufacturing operation in Athlone, Ireland, to produce the tablet form of its weight loss drug Wegovy.
Novo Nordisk has significantly cut the prices of its weight-loss drug Wegovy by half, as the company's stock approaches a 52-week low.
Novo Nordisk announced plans to reduce the U.S. list prices for its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50%. This move aims to make the medications more affordable for patients.
Novo Nordisk announced plans to reduce the U.S. list prices for its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50%.
Novo Nordisk is reducing the list price of its weight-loss drug Wegovy and diabetes drug Ozempic in the USA to improve patient access.
This article explains the mechanisms of action for popular weight-loss drugs like Mounjaro and Wegovy, detailing how they work and their current availability to patients through the NHS and private markets.
Shares of Novo Nordisk, owner of Wegovy and Ozempic, fell sharply after its highly anticipated next-generation weight-loss drug, CagriSema, failed to meet investor expectations in testing, leading it to be branded 'obsolete'.
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
The European Union has given its approval for a higher dose of Novo Nordisk's popular weight-loss medication, Wegovy.